Floatz logo

Therapeutic Asset Ratings

4,361 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Cediranib
Recurrent Childhood Malignant Germ Cell Tumor
National Cancer Institute (NCI)P2BB (64)
Cediranib
Wilms Tumor
National Cancer Institute (NCI)P2BB (64)
CIS-DIAMMINEDICHLOROPLATINUM II
Appendix Cancer
National Cancer Institute (NCI)P2BB (64)
CIS-DIAMMINEDICHLOROPLATINUM II
Peritoneal Mesothelioma
National Cancer Institute (NCI)P2BB (64)
CIS-DIAMMINEDICHLOROPLATINUM II
Stage III Cervical Cancer
National Cancer Institute (NCI)P2BB (64)
Cyclophosphamide
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
National Cancer Institute (NCI)P2BB (64)
CYCLOSPORIN A
Immune System Diseases
National Cancer Institute (NCI)P2BB (64)
Cytosin-Arabinosid
Acute Myeloid Leukemia And Myelodysplastic Syndromes Related To Alkylating Agent
National Cancer Institute (NCI)P2BB (64)
ETOPOSIDE
B-Cell Adult Acute Lymphocytic Leukemia
National Cancer Institute (NCI)P2BB (64)
ETOPOSIDE
CD20 Positive
National Cancer Institute (NCI)P2BB (64)
ETOPOSIDE
Neuroendocrine Neoplasm
National Cancer Institute (NCI)P2BB (64)
Gemtuzumab Ozogamicin
Acute Monocytic Leukemia
National Cancer Institute (NCI)P2BB (64)
Gemtuzumab Ozogamicin
Adult Acute Monocytic Leukemia
National Cancer Institute (NCI)P2BB (64)
Gemtuzumab Ozogamicin
Acute Myeloblastic Leukemia Without Maturation
National Cancer Institute (NCI)P2BB (64)
Gemtuzumab Ozogamicin
Acute Myelomonocytic Leukemia M4
National Cancer Institute (NCI)P2BB (64)
Gemtuzumab Ozogamicin
Acute Erythroid Leukemia
National Cancer Institute (NCI)P2BB (64)
Ibrutinib
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)P2BB (64)
Inno-206
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
National Cancer Institute (NCI)P2BB (64)
Irinotecan
Myelodysplastic Syndrome With Ring Sideroblasts
National Cancer Institute (NCI)P2BB (64)
Irinotecan
Peritoneal Mesothelioma
National Cancer Institute (NCI)P2BB (64)
Irinotecan
Refractory Anemia
National Cancer Institute (NCI)P2BB (64)
Nilotinib
Breast Cancer
National Cancer Institute (NCI)P2BB (64)
Nilotinib
Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute (NCI)P2BB (64)
Nivolumab
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)P2BB (64)
Nivolumab
Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)P2BB (64)
Showing 451 to 475 of 4,361 assets
PreviousPage 19 of 175Next